Breast Cancer Research Articles & Analysis
35 news found
Breast cancer remains one of the most challenging diseases to treat, especially for aggressive forms such as triple-negative breast cancer. Researchers are working relentlessly to better understand tumor metabolism and to find new therapeutic strategies. Two recent studies highlight how critical glutamine ...
The research, which will take place in the laboratory of Dr. Massimo Cristofanilli, a Professor of Medicine at Weill Cornell Medicine, and at Tethis, will focus on patients with early-stage breast cancer who are given drugs to reduce tumor size, prior to surgery to remove the tumors. ...
Aditya Bardia, MD, MPH, Director of Breast Cancer Research at Mass General Cancer Center, Associate Professor at the Medicine Department at Harvard Medical School, and Principal Investigator for the EMERALD trial. ...
“Menarini will continue to pursue research collaborations that have the potential to improve patients’ lives in breast ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
Fine, Director of Education & Research, Margaret West Comprehensive Breast Center, West Cancer Center & Research Institute, stated, “We are excited to be the first site to enroll a patient in the Perimeter pivotal trial that is evaluating the use of Perimeter B-Series OCT imaging technology combined with artificial ...
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at ...
Fine, Director of Education & Research, Margaret West Comprehensive Breast Center, West Cancer Center & Research Institute, commented, “I believe combining optical coherence tomography with artificial intelligence could represent the ‘next generation’ technology in specimen imaging. As ...
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in ...
The parties at the signing ceremony have agreed to co-develop Breast Cancer Centers of Excellence which will deliver comprehensive, compassionate breast cancer care combined with advanced basic and translational cancer research. ...
4D Path, creator of a patented computer-aided pan-cancer diagnostic and precision oncology platform, is pleased to announce that Dr. ...
This study will recruit participants from a territory-wide cancer screening program in Hong Kong who will also undergo breast-dedicated MRI. ...
The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge, a randomized clinical study to evaluate a novel investigational surgical device for the treatment of breast cancer-related lymphedema. This study is sponsored by Fibralign Corporation with funding provided by the National Cancer Institute ...
Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National Comprehensive Cancer Network ...
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the University of Leeds in the UK through 2027, the two organizations announced today. Through a prior three-year partnership, 4D Path has already successfully completed three breast cancer clinical studies at Leeds with striking results. Cases from over ...
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative ...
Study results presented at ASCO20 showed that the Recurrence Score results on core biopsies predict the likelihood of response to neoadjuvant chemotherapy Results are particularly relevant in the context of the Covid-19 pandemic which is causing the delay of elective surgeries across health systems worldwide Exact Sciences Corp. today announced results from three studies of the Oncotype DX ...
This October Iowa drivers raised over $20,000 for breast cancer research and support services simply by choosing cleaner-burning Unleaded 88 during the 4th annual Pink at the Pump® campaign, co-sponsored by the Iowa Renewable Fuels Association (IRFA) and Iowa Corn Promotion Board (ICPM). ...
McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium New Publication of Long-term Data from Real-world Clinical Practice Confirms Conclusions of TAILORx Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio Breast ...
A recent survey of women in the Netherlands found that 79 percent of respondents diagnosed with breast cancer noticed symptoms prior to being diagnosed. Seno Medical Instruments, Inc. (Seno Medical), a Texas-based medical imaging company developing breakthrough breast cancer diagnostic technology, teamed up with the Know Your Lemons campaign to conduct the survey in the Netherlands, which has ...